John P. Dunphy
Profile
John P.
Dunphy worked as a Managing Director at Equity Capital Markets Ltd., a Chief Financial Officer at Idenix Pharmaceuticals LLC, a Chief Financial Officer, Treasurer & VP at Paratek Pharmaceuticals, Inc., and a Senior Vice President at Butcher & Singer, Inc. He received an undergraduate degree from Boston College and an MBA from The Ohio State University.
Former positions of John P. Dunphy
| Companies | Position | End |
|---|---|---|
| Equity Capital Markets Ltd. | President | - |
| IDENIX PHARMACEUTICALS INC | Director of Finance/CFO | - |
| Butcher & Singer, Inc. | Corporate Officer/Principal | - |
Paratek Pharmaceuticals, Inc. /Old/
 Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Director of Finance/CFO | - |
Training of John P. Dunphy
| Boston College | Undergraduate Degree |
| The Ohio State University | Masters Business Admin |
Experiences
Positions held
Linked companies
| Private companies | 4 |
|---|---|
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
| Butcher & Singer, Inc. | Finance |
| Equity Capital Markets Ltd. | Finance |
- Stock Market
- Insiders
- John P. Dunphy
